Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BHQ880 in Untreated Multiple Myeloma with Renal Insufficiency
NCT01337752Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2012
- Primary completion
- May 2013
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of BHQ880 in multiple myeloma (MM), sponsored by Novartis. Started Jan 2012; status: completed.
02
Drugs
BHQ880
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01337752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01337752.